Interleukin 18: Friend or foe in cancer

被引:50
|
作者
Palma, Giuseppe [1 ,5 ]
Barbieri, Antonio [1 ]
Bimonte, Sabrina [1 ]
Palla, Marco [2 ]
Zappavigna, Silvia [4 ]
Caraglia, Michele [4 ]
Ascierto, Paolo A. [2 ]
Ciliberto, Gennaro [3 ]
Arra, Claudio [1 ]
机构
[1] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, Struttura Semplice Dipartimentale Sperimentaz Ani, Milan, Italy
[2] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, UOC Oncol Med & Terapie Innovat, Milan, Italy
[3] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, Milan, Italy
[4] Univ Naples 2, Dipartimento Biochim & Biofis & Patol Gen, I-80138 Naples, Italy
[5] CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy
来源
关键词
Tumor immunology; Immune regulation; GAMMA-INDUCING FACTOR; MURINE MELANOMA-CELLS; ENDOTHELIAL GROWTH-FACTOR; HUMAN GASTRIC-CANCER; IFN-GAMMA; SIGNALING PATHWAYS; INTERFERON-GAMMA; BINDING-PROTEIN; ANTITUMOR-ACTIVITY; IMMUNE ESCAPE;
D O I
10.1016/j.bbcan.2013.09.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the last few years, the field of tumor immunology has significantly expanded and its boundaries, never particularly clear, have become less distinct. Although the immune system plays an important role in controlling tumor growth, it has also become clear that tumor growth can be promoted by inflammatory immune responses. A good example that exemplifies the ambiguous role of the immune system in cancer progression is represented by interleukin 18 (IL-18) that was first identified as an interferon-gamma-inducing factor (IGIF) involved in T helper type-1 (Th1) immune response. The expression and secretion of IL-18 have been observed in various cell types from immune cells to circulating cancer cells. In this review we highlighted the multiple roles played by IL-18 in immune regulation, cancer progression and angiogenesis and the clinical potential that may result from such understanding. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:296 / 303
页数:8
相关论文
共 50 条
  • [1] Interleukin-18 in Intestinal Inflammation: Friend and Foe?
    Siegmund, Britta
    IMMUNITY, 2010, 32 (03) : 300 - 302
  • [2] Interleukin-18: Friend or Foe for Systemic Sclerosis?
    Pan, Hai-Feng
    Wang, Jing
    Leng, Rui-Xue
    Li, Xiang-Pei
    Ye, Dong-Qing
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (12) : 2495 - 2495
  • [3] Response to "Interleukin-18: Friend or Foe for Systemic Sclerosis?"
    Kim, Hei Sung
    Kim, Hee Jung
    Cho, Dae Ho
    Park, Hyun Jeong
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (12) : 2496 - 2497
  • [4] Interleukin-21 in cancer immunotherapy Friend or foe?
    Stolfi, Carmine
    Pallone, Francesco
    Macdonald, Thomas T.
    Monteleone, Giovanni
    ONCOIMMUNOLOGY, 2012, 1 (03) : 351 - 354
  • [5] Interleukin-22: friend or foe?
    Hasnain, Sumaira Z.
    Begun, Jakob
    IMMUNOLOGY AND CELL BIOLOGY, 2019, 97 (04): : 355 - 357
  • [6] Interleukin-22-Friend or Foe?
    Leipe, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2015, 74 (01): : 51 - 53
  • [7] Interleukin 27 in psoriasis: Friend or foe?
    EL-Komy, Mohamed H. M.
    Ahmed, Heba
    Mourad, Ahmed
    Shaker, Olfat Gamil
    AlOrbani, Aya M.
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2022, 88 (06): : 843 - 845
  • [8] INTERLEUKIN-15 AND SEPSIS: FRIEND OR FOE?
    Guo, Y.
    Sherwood, E.
    SHOCK, 2013, 39 : 32 - 32
  • [9] Interleukin-17: friend or foe in atherosclerosis?
    Taleb, Soraya
    Tedgui, Alain
    Mallat, Ziad
    CURRENT OPINION IN LIPIDOLOGY, 2010, 21 (05) : 404 - 408
  • [10] Neuropeptides in Cancer: Friend and Foe?
    Wu, Yue
    Berisha, Adrian
    Borniger, Jeremy C.
    ADVANCED BIOLOGY, 2022, 6 (09):